WO WO2026115500A1
The present disclosure introduces a sprayable formulation for the enhanced treatment of inflammatory bowel disease (IBD). A lyophilized formulation (102) comprises probiotic- derived extracellular vesicles (EVs) (104) sourced from the VSL#3 probiotic blend, encapsulated within a thermo-responsive polymer matrix (106) made from poly(N-isopropyl acrylamide) (PNIPAM) and hyaluronic acid. Available as an off-the-shelf lyophilized powder, the formulation (102) is easy to store and rehydrate for use. Upon application, the lyophilized formulation (102) undergoes a phase transition at physiological temperature, forming a gel-like coating over the inflamed areas of the gut. This matrix (106) ensures localized delivery of the encapsulated EVs (104) directly to the disease site. The combination of hyaluronic acid and probiotic-derived EVs (104) reduces inflammation and promotes mucosal healing, addressing critical aspects of gut health in IBD management.
A document turning up in a search is not the same as a document that anticipates your claims. Our registered Patent Agents read the claims, not just the abstract, and tell you where you still have room.
Protect Your InventionBibliographic data via the European Patent Office's Open Patent Services (DOCDB) . Republished here for research and prior-art review. This page is not legal advice, and its presence in our index says nothing about the validity or enforceability of the document. For the Indian legal position (status, oppositions, renewals), see InPASS.